TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7512838
Drug: G-CSF (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (200 microgram/m2) starting daily from 2 days before induction therapy until neutrophils recovered to above 1,500/microL or until 35 days after therapy
Study: 30889155
Drug: Fisionerv® gel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fisionerv® gel, 3 times/day added to physiotherapy (40 minutes daily session)
Study: 30889155
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle gel (placebo, 3 times/day) added to physiotherapy (40 minutes daily session)
Study: 30889155
Drug: Fisionerv® gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fisionerv® gel
Study: 23297841
Drug: VEN‐XR (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEN‐XR (up to 375 mg)
Study: 21783417
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg/day) until disease progression or unacceptable toxic effects
Study: 21783417
Drug: Chemotherapy (gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (gemcitabine plus carboplatin)
Study: 17087700
Drug: Individual vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual vitamin or mineral supplement
Study: 17087700
Drug: Nonvitamin/nonmineral dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonvitamin/nonmineral dietary supplement (NVNMDS)
Study: 15234411
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance test in patients with IDCM
Study: 19821105
Drug: rabdosia rubescens
Normalized name: Isodon rubescens top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabdosia rubescens drop pill (960 mg) and 4 tablets of simulation agent, administered three times a day for 5 days
Study: 19821105
Drug: rabdosia rubescens
Normalized name: Isodon rubescens top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabdosia rubescens tablet (1000 mg) and 24 drop pills of simulation agent, administered three times a day for 5 days
Study: 17760546
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel in a silica base for 2 minutes (G1)
Study: 17760546
Drug: Neutral EDTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral EDTA conditioning agent for 2 minutes followed by placebo gel (G2)
Study: 17760546
Drug: 0.12% CHX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% CHX digluconate gel in a silica base (G3)
Study: 17760546
Drug: Neutral EDTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral EDTA conditioning agent for 2 minutes followed by CHX gel (G4)
Study: 11172955
Drug: Post-treatment PCR
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment PCR results
Study: 31151390
Drug: Arm 1
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm 1 (Usual Care): 10% cash back, no weekly text, standard monthly text
Study: 31151390
Drug: Arm 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 2: 10% cash back, generic weekly text, standard monthly text
Study: 16844713
Drug: Intravenous levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous levodopa infusion
Study: 10752492
Drug: Melatonin 3
Normalized name: melatonin 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 3 mg at bedtime
Study: 9203718
Drug: Oral poliovirus
Normalized name: poliovirus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral poliovirus vaccine (OPV) during NID
Study: 8381091
Drug: In vivo
Normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vivo prednisolone treatment
Study: 3079540
Drug: 4.5 X
Normalized name: Hydrocodone Bitartrate and Acetaminophen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4.5 X 10(6) U IFN‐beta ser i.v. daily for 10 days
Study: 3079540
Drug: 90 X
Normalized name: insulin, regular, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 X 10(6) U IFN‐beta ser i.v. daily for 10 days
Study: 26300329
Drug: Cognitive Therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Therapy (CBT and NCT combined)
Study: 18498589
Drug: Early loading
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early loading of dental implants
Study: 18498589
Drug: Moderately rough
Normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately rough surface implants
Study: 18498589
Drug: Novel one-piece
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel one-piece implant design
Study: 12549992
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (not specified dosage or duration)
Study: 12549992
Drug: Raloxifene (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (specific dosage and duration not mentioned)
Study: 8816210
Drug: Dexamethasone therapy
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone therapy (0.5 mg/kg per day for 5 days)
Study: 8112809
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg zinc/p.o./day as 200 mg 'zinc sulphate tablets
Study: 8112809
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no zinc administration)
Study: 25346818
Drug: Caudal injection
Normalized name: LIDOCAINE HYDROCHLORIDE 10 mg in 1 mL INTRACAUDAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal injection
Study: 25346818
Drug: Transforaminal injection
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal injection
Study: 21692827
Drug: Infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg kg⁻¹ infusions at weeks 0, 2, 6, 12 and 18
Study: 21692827
Drug: Infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg kg⁻¹ infusions
Study: 20601389
Drug: Higher in-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher in-treatment HR in time-varying multivariable Cox models
Study: 1815112
Drug: Interpleural block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpleural block (IPB) with 10 ml 0.5% plain bupivacaine (n = 15)
Study: 1815112
Drug: Spinal analgesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal analgesia with 15 mg 0.5% heavy bupivacaine and meperidine 1 mg/kg IV and diazepam 10 mg total dose (n = 10)
Study: 25376160
Drug: Prolonged-release trazodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release trazodone (150-450 mg)
Study: 22289412
Drug: Infant formula
Normalized name: Infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant formula supplemented with complex milk lipid (11 to 12 μg/ml gangliosides)
Study: 19889508
Drug: Control period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control period (weekly educational newsletters)
Study: 18303079
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogens (CEEs) 0.625 mg/d for 12 weeks
Study: 18303079
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (E2) 0.05 mg/d for 12 weeks
Study: 16002420
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of piperacillin/tazobactam (13.5 g over 24 h)
Study: 16002420
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion of piperacillin/tazobactam (3.375 g every 6 h)
Study: 16002420
Drug: Both infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both infusion methods (intermittent and continuous)
Study: 8770708
Drug: Intensive plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive plasma exchange (IPE) or whole blood exchange (WBE) in addition to standard medical therapy
Study: 2061418
Drug: Preventive program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive program based on plaque control and topical application of fluoride, with scaling, root planning, and conventional caries therapy; preventive measures recalled every 2-3 months for 6 years, then 1-2 times per year for 9 years, with a subgroup recalled 3-6 times per year.
Study: 6349652
Drug: Meclofenamate sodium
Normalized name: Meclofenamate Sodium
DrugBank: Meclofenamic acid (DB00939)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meclofenamate sodium (300 mg per day for 4 weeks)
Study: 28403154
Drug: 56mg/day magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 56mg/day magnesium cream
Study: 21136163
Drug: Other antihypertensive
Normalized name: Other antihypertensives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antihypertensive medications
Study: 21136163
Drug: No antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antihypertensive medications
Study: 19070525
Drug: Nitazoxanide (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide (15 mg/kg/day, twice a day for three days)
Study: 19070525
Drug: Probiotics (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (1 g, twice a day for five days)
Study: 19070525
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution (control)
Study: 11385811
Drug: Established inhalational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Established inhalational devices (pressurized metered dose inhalers)
Study: 7978134
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam 0.5 mg.kg-1
Study: 25693013
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of propranolol per kilogram per day for 6 months
Study: 25693013
Drug: Propranolol (successful
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (successful treatment)
Study: 22118955
Drug: Quercetin 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin 150 mg/d for 8 weeks
Study: 19758254
Drug: Photodynamic antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic antimicrobial therapy (PACT) with 47 J cm(‐2) of irradiation
Study: 19758254
Drug: Photodynamic antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic antimicrobial therapy (PACT) with 94 J cm(‐2) of irradiation
Study: 11435905
Drug: Lofepramine and
Normalized name: lofepramine
DrugBank: Lofepramine (DB13411)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lofepramine and L-phenylalanine
Study: 7844206
Drug: Gonadotrophin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotrophin-releasing hormone agonist (GnRH-a) in a long-term protocol with human menopausal gonadotrophin (HMG)
Study: 7844206
Drug: Gonadotrophin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotrophin-releasing hormone agonist (GnRH-a) in a short protocol with human menopausal gonadotrophin (HMG)
Study: 3132484
Drug: 2000‐mg calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000‐mg calcium diet for 8 weeks
Study: 3132484
Drug: 300‐mg calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300‐mg calcium diet for 1, 2, 4, and 8 weeks
Study: 27644469
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab injections
Study: 22388304
Drug: Nitroglycerin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin plus diltiazem (200 μg nitroglycerin plus 2.5 mg diltiazem)
Study: 22388304
Drug: Nitroglycerin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin alone (200 μg nitroglycerin plus placebo)
Study: 15665739
Drug: Sirolimus maintenance
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus maintenance therapy after cyclosporine withdrawal
Study: 7861018
Drug: Stavudine at
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stavudine at 0.1 mg/kg/day
Study: 7861018
Drug: Stavudine at
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stavudine at 0.5 mg/kg/day
Study: 7861018
Drug: Stavudine at
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stavudine at 2.0 mg/kg/day
Study: 1953510
Drug: Flexible dose
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible dose induction protocol
Study: 1953510
Drug: Empirical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical treatment by resident medical staff
Study: 7372069
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subsalicylate therapy
Study: 22336250
Drug: Propionyl-L-carnitine (PLC)
Normalized name: glycine propionyl-L-carnitine
DrugBank: Levocarnitine propionate (DB15980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionyl-L-carnitine (PLC) 6g/day
Study: 21771118
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment (n=342)
Study: 21771118
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (n=346)
Study: 19947445
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy (various classes including diuretics, calcium antagonists, ACE inhibitors, and angiotensin II receptor antagonists)
Study: 17172556
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (motor imagery and physical practice)
Study: 17172556
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy alone (control group)
Study: 7696942
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (Sandoglobulin, Sandoz Pharmaceuticals) at a dose of 700 mg/kg for infants weighing 501-1000 g and 900 mg/kg for those weighing 1001-1500 g, repeated every 14 days until 1800 g or discharge/death
Study: 7696942
Drug: Placebo infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusions during phase I (n = 623), no infusion during phase II (n = 589)
Study: 2577441
Drug: Chlordesmethyldiazepam 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlordesmethyldiazepam 0.1 mg/kg‐1 i.v. (group C)
Study: 2577441
Drug: Sodium thiopental
Normalized name: Thiopental Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium thiopental 5 mg/kg‐1 i.v. (Group T)
Study: 389815
Drug: Co-trimazine (410
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimazine (410 mg sulphadiazine plus 90 mg trimethoprim)
Study: 389815
Drug: Co-trimoxazole (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (800 mg sulphamethoxazole plus 160 mg trimethoprim)
Study: 25151583
Drug: Orthodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic treatment with premolar extraction (n = 30)
Study: 25151583
Drug: Orthodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic treatment without premolar extraction (n = 34)
Study: 25151583
Drug: Control group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group, no orthodontic treatment (n = 65)
Study: 19617465
Drug: Golimumab (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab (50 mg or 100 mg every 4 weeks)
Study: 17877100
Drug: Hormone status,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone status, gynecologic surgery, alcohol intake, age, educational attainment
Study: 3289931
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diltiazem plus digoxin
Study: 28267480
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg betrixaban
Study: 28267480
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg betrixaban
Study: 21736887
Drug: Acetazolamide (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (7 mg/kg)
Study: 21736887
Drug: Saline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline treatment (control)
Study: 18426998
Drug: N(G)‐monomethyl‐l‐arginine (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: N(G)‐monomethyl‐l‐arginine (lower dose)
Study: 18426998
Drug: Sildenafil (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (25 mg PO)
Study: 18426998
Drug: N(G)‐monomethyl‐l‐arginine (infusion)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N(G)‐monomethyl‐l‐arginine (infusion)
Study: 18426998
Drug: Phenylephrine (equipressor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (equipressor doses)
Study: 16568340
Drug: Vibration muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibration muscle exercise (RVE, 2x6 min daily)
Study: 8565026
Drug: HCQ 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCQ 800 mg/d
Study: 2201541
Drug: Slow-release carbamazepine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release carbamazepine (SR) preparation
Study: 2201541
Drug: Conventional carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional carbamazepine (C) preparation
Study: 7302260
Drug: 100 mcg
Normalized name: Levo-T 100 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mcg 15(R)-15-methyl prostaglandin E2 (PG)
Study: 28865815
Drug: Anti-inflammatory drugs
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory drugs only (Group A)
Study: 28865815
Drug: Antibiotics for
Normalized name: ANTIBIOTICS FOR TOPICAL USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics for 3 days + anti-inflammatory drugs (Group B)
Study: 28865815
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of antibiotic 1 hour before extraction + anti-inflammatory drugs (Group C)
Study: 28865815
Drug: Mouthwash for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouthwash for 7 days + anti-inflammatory drugs (Group D)
Study: 25919834
Drug: Impaired insight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impaired insight into delusions (assessed after 3 weeks of treatment)
Study: 25919834
Drug: Impaired insight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impaired insight into delusions (assessed after 6 weeks of treatment)
Study: 25919834
Drug: Impaired insight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impaired insight into delusions (assessed after 8 weeks of treatment)
Study: 19609738
Drug: CRP levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP levels ≥7 mg/L
Study: 19609738
Drug: CRP levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP levels <7 mg/L
Study: 7920977
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (lipid-supplemented solution)
Study: 7920977
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I (predominantly carbohydrate solution)
Study: 30947825
Drug: Landmark-based injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landmark-based injection
Study: 28961996
Drug: Amoxicillin-containing regimens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-containing regimens
Study: 28961996
Drug: Clarithromycin triple
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin triple therapy
Study: 28961996
Drug: Breakpoint of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breakpoint of amoxicillin resistance ≥0.125 mg/L
Study: 20501520
Drug: Remifentanil (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0.3 μg/kg/min)
Study: 22935482
Drug: ACEI therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI therapy
Study: 17144553
Drug: Muscular contrapulsation
Normalized name: Orchis mascula whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscular contrapulsation (MCP) in combination with balneotherapy (radon and iodine-bromine baths)
Study: 14658990
Drug: Systematic approach
Normalized name: Integrase Inhibitors, antiinfectives for systematic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic approach to treatment including patient education, encouragement of exposure, attention to relevant comorbidities, use of empirically proven pharmacotherapies, and psychosocial interventions of adequate intensity and duration.
Study: 8736458
Drug: Indomethacin treatment
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin treatment for 1 month
Study: 1550474
Drug: Liquid oral
Normalized name: M-End Liquid Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid oral intake 4 hours after removal of the tube
Study: 3875296
Drug: 0.03 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg/kg bwxh nimodipine
Study: 3875296
Drug: 0.06 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06 mg/kg bwxh nimodipine
Study: 28058753
Drug: gemigliptin 50
Normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemigliptin 50 mg
Study: 31502749
Drug: gemigliptin 50
Normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemigliptin 50 mg and dapagliflozin 10 mg
Study: 22491353
Drug: Oral alpha‐methyl‐para‐tyrosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral alpha‐methyl‐para‐tyrosine (AMPT)